Roy Buchanan

Stock Analyst at Citizens Capital Markets

(0)
# 4745
Out of 5,298 analysts
64
Total ratings
23.08%
Success rate
-25.50%
Average return
18 Stocks
Name Action Price Target Current % Upside Ratings Updated
ANTX AN2 Therapeutics
Reiterates: Market Outperform
5 5
1.27 293.7% 8 Mar 26, 2025
INO Inovio Pharmaceuticals
Reiterates: Market Outperform
18 18
1.55 1061.29% 3 Mar 14, 2025
CDTX Cidara Therapeutics
Initiates Coverage On: Market Outperform
46
16.35 181.35% 1 Mar 12, 2025
CVAC CureVac
Reiterates: Market Outperform
16 16
2.6 515.38% 8 Feb 14, 2025
TPG TPG
Reiterates: Market Perform
n/a
n/a n/a 1 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
7 4
1.23 225.2% 3 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
21 21
4.74 343.04% 12 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
23 14
1.34 944.78% 1 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
33 33
5.24 529.77% 1 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
24 7
0.83 743.37% 2 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 5 Oct 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
4 5
3.24 54.32% 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
25 27
12.64 113.61% 5 Nov 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Jul 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
443 448
554.62 -19.22% 2 Mar 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
14 16
5.87 172.57% 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Feb 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Outperform
420
2.51 16633.07% 1 Sep 14, 2021